Three ETFs To Watch On Biotech Earnings

The earnings season is off to a flying start, owing to a slew of upbeat economic data, strong corporate performance, and President Donald Trump's tax reform signed into law. However, equity markets have been suffering a sell-off owing to fears of rising rates. Coming to the performance of biotech giants, it has been a mixed bag for biotech companies, with some beating market expectations, while a few failing to do so.

We will now discuss the performance of a few biotech giants such as Amgen Inc (AMGN - Free Report), Gilead Sciences (GILD - Free Report), Biogen Inc (BIIB - Free Report) and Alexion Pharmaceuticals (ALXN - Free Report).

Earnings in Focus

Amgen reported fourth-quarter 2017 adjusted earnings of $2.89 per share, missing the Zacks Consensus Estimate of $3.04, but unchanged from the year-ago quarter. The company also missed the Zacks Consensus Estimate on revenues. Amgen reported revenues of $5.802 billion, missing the Zacks Consensus Estimate of $5.856 billion and decreasing 2.7% from $5.965 billion in the year-ago quarter.

For full-year 2017, the company reported a 1% decrease in revenues to $22.849 billion. However, Non-GAAP EPS increased 8% to $12.58.

The company expects its 2018 non-GAAP EPS to be in the range $12.6-$13.7. It also expects its revenues to be in the range of $21.8-$22.8 billion. Moreover, Amgen expects adjusted tax rate to be around 14-15% in 2018, owing to the tax reform.

Gilead Sciences reported fourth-quarter 2017 adjusted earnings of $1.78 per share, surpassing the Zacks Consensus Estimate of $1.70 but decreasing around 34.1% from $2.70 per share in the year-ago quarter. Moreover, the company also beat the Zacks Consensus Estimate on revenues. The company reported revenues of $5.949 billion, surpassing the Zacks Consensus Estimate of $5.776 billion but decreasing more than 18.7% from $7.320 billion in the year-ago quarter.

For full-year 2017, the company reported a 14.1% decrease in revenues to $26.107 billion. Moreover, Non-GAAP EPS decreased 23.6% to $8.84 in the period.

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.